GlassScriptPhysician profile
Xiaoyu Li
NPI 1205275799
$4,119.80
in general payments reported to CMS, 2019-2025
15 companies · $1,407 in 2025
The $1,407 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2020: $65.52 · 2021: $160 · 2022: $495 · 2023: $791 · 2024: $1,062 · 2025: $1,407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,260.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $948.42 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $592.14 | 2022-2025 | Farxiga, Airsupra |
| Amgen INC. | $485.48 | 2022-2025 | Otezla, Repatha, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $410.99 | 2023-2024 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Bayer Healthcare Pharmaceuticals INC. | $253.60 | 2024-2025 | Kerendia |
| Novo Nordisk INC | $235.36 | 2022-2025 | Ozempic, Rybelsus |
| Kowa Pharmaceuticals America, INC. | $210.44 | 2024-2025 | Zoryve |
| Madrigal Pharmaceuticals | $175.09 | 2025 | Rezdiffra |
| Abbvie INC. | $146.42 | 2022 | |
| Insmed, INC. | $138.89 | 2019 | |
| Abbott Laboratories | $136.15 | 2022 | |
| Ibsa Pharma INC. | $121.12 | 2021-2023 | Tirosint, Licart |
| Gilead Sciences, INC. | $120.17 | 2021-2023 | Vemlidy |
| Merck Sharp & Dohme LLC | $115.52 | 2020-2022 | |
| Genentech USA, INC. | $30.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xiaoyu Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.